CA209-714
12 april 2021
Archief
CA209-76K
A phase 3, randomized, double-blind study of adjuvant immunotherapy with Nivolumab versus placebo after complete resection of stage IIB/C melanoma (CA209-76K) Protocolnummer: CA20976K EudraCT nummer: 2019-001230-34 METc nummer:…
CA209-901
A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer (CheckMate 901:…
CAIRO3
Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab as first-line treatment in patients with advanced colorectal carcinoma, a randomised phase III…
CAIRO3
CAIRO6
De waarde van peri-operatieve systemische therapie in patiënten die cytoreductieve chirurgie en HIPEC ondergaan voor het peritoneaal gemetastaseerd colorectaal carcinoom: de multicenter, fase II-III, prospectieve, gerandomiseerde CAIRO6 studie….
CAIRO6
De waarde van peri-operatieve systemische therapie in patiënten die cytoreductieve chirurgie en HIPEC ondergaan voor het peritoneaal gemetastaseerd colorectaal carcinoom: de multicenter, fase II-III, prospectieve, gerandomiseerde CAIRO6 studie….
CEMangio
4 juli 2022
Behandeling met cemiplimab van patiënten met lokaal vergevorderd of gemetastaseerd secundair angiosarcoom. Eudractnummer: 2020-005465-13 Samenvatting In deze fase II studie kunnen patiënten met een lokaal vergevorderd of gemetastaseerd…
Checkmate studie RCC CA209-214
12 april 2021
CA209-214: A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma Protocolnummer: CA209-214…
Columbus
A Phase III randomized, 3-arm, open label, multicenter study of LGX818 plus MEK162 and LGX818 monotherapy compared with vemurafenib in patients with unresectable or metastatic BRAF V600 mutant…
Columbus-AD
7 december 2022
Adjuvante Encorafenib en Binimetinib versus placebo in volledig gereseceerd BRAF V600E/K-gemuteerd stadiumIIB/C melanoom: een gerandomiseerd driedubbelblind fase III-onderzoek in samenwerking met de EORTC Melanoma Group. Protocolnummer: W00090GE303 /…
COMBI-AD
12 april 2021
A phase III randomized double blind study of dabrafenib (GSK2118436) in COMBInation with trametinib (GSK1120212) versus two placebos in the ADjuvant treatment of high-risk BRAF V600 mutation-positive melanoma…
Comet-1
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs. Prednisone in Metastatic Castrationresistant Prostate Cancer Patients who have Received Prior Docetaxel and Prior Abiraterone or MDV3100.
CPCT-02
6 mei 2021
Development of a platform for next-generation DNA sequencing based personalized treatment for cancer patients: Protocol to obtain biopsies from patients with advanced (incurable) or metastatic cancer (CPCT –…
CTMX-M-072-001 (PROCLAIM-001)
5 mei 2021
An open-label, dose-finding and proof of concept study of the PD-L1 probody™ therapeutic, CX-072, as monotherapy and in combination with yervoy (ipilimumab) or with zelboraf (vemurafenib) in subjects…
CYCLONE-3
24 november 2022
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination with Abiraterone plus Prednisone in Men with High-Risk Metastatic Hormone-Sensitive Prostate Cancer EU trial number: 2022-500461-28-06 Samenvatting…
D6020C00001 studie MEDI0680 + durvalumab versus nivolumab
12 april 2021
A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination with Durvalumab versus Nivolumab Monotherapy in Subjects with Select Advanced Malignancies….
DANUBE
A phase III, randomized, open-label, controlled, multi center, global study of first-line MEDI4736 monotherapy and MEDI4736 in combination with tremelimumab versus standard of care chemotherapy in patients with…
DCC-2618-03-002 (intrigue)
A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib Protocolnummer: DCC-2618-03-002 EudraCT nummer: 2018-001803-35…
Destiny-PanTumor02
15 juni 2021
A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02) Protocolnummer D967VC00001…